Insider Selling: Invivyd (NASDAQ:IVVD) Insider Sells $16,095.60 in Stock

Posted by Brian Himes on Aug 18th, 2026

Invivyd, Inc. (NASDAQ:IVVD – Get Free Report) insider Julie Green sold 22,355 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $0.72, for a total transaction of $16,095.60. Following the completion of the transaction, the insider owned 187,362 shares in the company, valued at approximately $134,900.64. This represents a 10.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Julie Green also recently made the following trade(s):

On Tuesday, August 18th, Julie Green sold 18,425 shares of Invivyd stock. The shares were sold at an average price of $0.84, for a total transaction of $15,477.00.

Invivyd Stock Up 17.2%

Shares of NASDAQ IVVD traded up $0.13 during mid-day trading on Tuesday, reaching $0.87. 7,732,095 shares of the company were exchanged, compared to its average volume of 3,061,089. The company’s 50-day simple moving average is $0.77 and its 200-day simple moving average is $1.23. The stock has a market capitalization of $255.75 million, a P/E ratio of -2.63 and a beta of 0.71. Invivyd, Inc. has a twelve month low of $0.48 and a twelve month high of $3.07.

Invivyd (NASDAQ:IVVD – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%.The company had revenue of $14.29 million for the quarter, compared to the consensus estimate of $14.40 million. As a group, equities research analysts expect that Invivyd, Inc. will post -0.52 EPS for the current year.

Analysts Set New Price Targets

IVVD has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating on shares of Invivyd in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Invivyd in a research note on Friday, July 24th. Wall Street Zen lowered Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Finally, BTIG Research reiterated a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Invivyd has a consensus rating of “Hold” and an average target price of $8.00.

Read Our Latest Research Report on Invivyd

Institutional Trading of Invivyd

A number of institutional investors have recently bought and sold shares of the business. Jupiter Topco LLC acquired a new position in shares of Invivyd during the 2nd quarter worth approximately $30,048,000. Janus Henderson Group PLC raised its position in shares of Invivyd by 1.7% in the first quarter. Janus Henderson Group PLC now owns 33,094,330 shares of the company’s stock valued at $42,857,000 after buying an additional 551,188 shares in the last quarter. Perceptive Advisors LLC acquired a new stake in shares of Invivyd in the fourth quarter valued at approximately $53,809,000. BVF Inc. IL bought a new stake in shares of Invivyd in the fourth quarter valued at approximately $48,227,000. Finally, RA Capital Management L.P. bought a new stake in shares of Invivyd in the third quarter valued at approximately $18,831,000. Institutional investors own 70.36% of the company’s stock.

Invivyd News Summary

Here are the key news stories impacting Invivyd this week:

Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

About Invivyd

(Get Free Report)

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.